Lars Rydén
Impact in
-
- Cardiovascular Function and Risk Factors
- Heart Failure Treatment and Management
- Cardiac Health and Mental Health
- Antiplatelet Therapy and Cardiovascular Diseases
- Cardiac pacing and defibrillation studies
- Blood Pressure and Hypertension Studies
-
- Diabetes Treatment and Management
Papers in
-
- Cardiac electrophysiology and arrhythmias 21
- Cardiac pacing and defibrillation studies 19
- Heart Failure Treatment and Management 16
- Cardiac Arrhythmias and Treatments 16
- Cardiac Health and Mental Health 12
-
- Diabetes Treatment and Management 14
- Co-authors
- Eberhard Standl (6 shared papers)Anna Norhammar (17 shared papers)Milton Packer (4 shared papers)Paul W. Armstrong (4 shared papers)Barry M. Massie (4 shared papers)John George Franklin Cleland (4 shared papers)John David Horowitz (4 shared papers)Philip Alexander Poole-Wilson (3 shared papers)
- Journals
- European Heart Journal (19 papers)Journal of Cardiovascular Pharmacology (13 papers)Journal of the American College of Cardiology (11 papers)Pacing and Clinical Electrophysiology (10 papers)European Journal of Heart Failure (7 papers)
- Partner nations
- SwedenUnited StatesGermany
In The Last Decade
Lars Rydén
233 papers receiving 23.3k citations
Lars Rydén's Hit Papers
Peers
Comparison fields: 5 of 200
- Cardiology and Cardiovascular Medicine 9.7k
- Endocrinology, Diabetes and Metabolism 4.9k
- Internal Medicine 653
- Surgery 4.3k
- Family Practice 178
Countries citing papers authored by Lars Rydén
This map shows the geographic impact of Lars Rydén's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lars Rydén with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lars Rydén more than expected).
Fields of papers citing papers by Lars Rydén
This network shows the impact of papers produced by Lars Rydén. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lars Rydén. The network helps show where Lars Rydén may publish in the future.
Co-authors
The 25 scholars most cited alongside Lars Rydén, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 239 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) Hit paper breakdown → | 2012 | 7138 |
| 2 | 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD Hit paper breakdown → | 2019 | 3184 |
| 3 | Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease Hit paper breakdown → | 2017 | 1765 |
| 4 | Comparative Effects of Low and High Doses of the Angiotensin-Converting Enzyme Inhibitor, Lisinopril, on Morbidity and Mortality in Chronic Heart Failure Hit paper breakdown → | 1999 | 959 |
| 5 | Diabetes as a cardiovascular risk factor: An overview of global trends of macro and micro vascular complications Hit paper breakdown → | 2019 | 689 |
| 6 | Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial Hit paper breakdown → | 2017 | 671 |
| 7 | Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry Hit paper breakdown → | 2019 | 648 |
| 8 | Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial Hit paper breakdown → | 2019 | 492 |
| 9 | Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin Hit paper breakdown → | 2019 | 374 |
| 10 | 2007 | 319 | |
| 11 | 2003 | 293 | |
| 12 | 2005 | 284 | |
| 13 | 2000 | 273 | |
| 14 | 1999 | 260 | |
| 15 | 2017 | 254 | |
| 16 | 1994 | 251 | |
| 17 | 2016 | 233 | |
| 18 | 2020 | 228 | |
| 19 | 1996 | 223 | |
| 20 | 1997 | 221 |
About Lars Rydén
Lars Rydén is a scholar working on Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism, Pathology and Forensic Medicine, Radiology, Nuclear Medicine and Imaging and Nutrition and Dietetics, having authored 239 papers that have together received 24.8k indexed citations. Recurring topics across this work include Cardiac electrophysiology and arrhythmias (21 papers), Cardiac pacing and defibrillation studies (19 papers), Heart Failure Treatment and Management (16 papers), Cardiac Arrhythmias and Treatments (16 papers), Cardiac Ischemia and Reperfusion (15 papers), Cardiac Imaging and Diagnostics (15 papers), Diabetes Treatment and Management (14 papers) and Cardiac Health and Mental Health (12 papers). The work is most often cited by research in Cardiology and Cardiovascular Medicine (9.7k citations), Endocrinology, Diabetes and Metabolism (4.9k citations), Internal Medicine (653 citations), Surgery (4.3k citations) and Family Practice (178 citations). Lars Rydén has collaborated with scholars based in Sweden, United States and Germany. Frequent co-authors include Eberhard Standl, Anna Norhammar, Milton Packer, Paul W. Armstrong, Barry M. Massie, John George Franklin Cleland, John David Horowitz, Philip Alexander Poole-Wilson, Kristian A. Thygesen and Barry F. Uretsky. Their work appears in journals such as European Heart Journal, Journal of Cardiovascular Pharmacology, Journal of the American College of Cardiology, Pacing and Clinical Electrophysiology and European Journal of Heart Failure.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.